We have now published a video on 2 KEY Cancer markers:
The Neutrophil to Lymphocyte Ratio (NLR)
A search of the National Library of Medicine shows how important the NLR marker is in Cancer.
A simple title search in the National Library of Medicine reveals >1200 medical papers showing how the NLR predicts cancer outcomes. This MODIFIABLE risk factor is easily obtained from a CBC with differential blood panel - and is extraordinarily inexpensive.
Why isn't every oncologist performing this test and helping their patients have better cancer outcomes?
From the paper titled, "A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer."
Cancer incidence is increasing in the United Kingdom, the United States and worldwide (Ferlay, 2010). Although it is clear that the development of cancer has a genetic basis, recent work has demonstrated that the host inflammatory response plays an important role in carcinogenesis and disease progression (Colotta et al, 2009; Hanahan and Weinberg, 2011).
It is therefore of interest that the combination of haematological components of the systemic inflammatory response, specifically neutrophils and lymphocytes, termed the neutrophil lymphocyte ratio (NLR) have been shown to have prognostic value in patients with a variety of cancers (Walsh et al, 2005; Cho et al, 2009; Sarraf et al, 2009; Shimada et al, 2010; Azab et al, 2011; Sharaiha et al, 2011), as well as patients undergoing chemotherapy for cancer (Kao et al, 2010; Chua et al, 2011).
The NLR does have the advantage of its components being inexpensive and routinely measured in day-to-day oncological practice, and in current chemotheraputic cancer trials. Clearly, if such extensive data were to confirm the prognostic value and clinical utility of the NLR, this would be an important, relevant, clinical translational advance in the identification of cancer patients at high risk (Clarke et al, 2011).
Look below to find the times and links to our weekly webinars....
What is the Chronic Disease Support program?